Table 3.
A comparison of the paraclinical characteristics of a group of 16 pregnant women with GBS (pGBS) and a control group of 18 non-pregnant women with GBS (npGBS)
| pGBS, n = 16 | npGBS, n = 18 | |
|---|---|---|
| CSF increased protein contenta | 12 (80%) | 8 (50%) |
| Normal CSF analysisa | 3 (20%) | 8 (50%) |
| CMV infection | 5 (31%) | 2 (11%) |
| Parvovirus B19 infection | 1 (6%) | 0 |
| Campylobacter jejuni infection | 0 | 0 |
| Yersinia pseudotuberculosis infection | 0 | 1 (6%) |
| Mycoplasma pneumoniae infection | 0 | 1 (6%) |
| EBV infection | 0 | 1 (6%) |
| Sars-Cov2 infection | 0 | 1 (6%) |
| Antiganglioside antibodies in serumb | 3 (30%) | 7 (50%) |
| Demyelinating NCSc | 9 (64%) | 15 (88%) |
| Axonal NCSc | 2 (14%) | 1 (6%) |
| Axonal and demyelinating NCSc | 2 (14%) | 0 |
| Normal NCSc | 1 (7%) | 1 (6%) |
| Mean delay between GBS onset and EDX (days) | 13 ± 6 | 10 ± 7 |
Data are given as n (%) and means ± SD. Percentages may not sum to 100 because of rounding
CMV cytomegalovirus, CSF cerebrospinal fluid, EBV Epstein-Barr virus, EDX electrodiagnostic studies, GBS Guillain-Barré syndrome, NCS nerve conduction studies, Sars-Cov2 severe acute respiratory syndrome coronavirus 2
aCSF analysis was performed in 15/16 pGBS and 16/18 npGBS cases
bAntiganglioside antibodies were investigated in 10/16 pGBS and 14/18 npGBS cases
cEDX studies were not performed in 2/16 pGBS and 1/18 npGBS cases. Initial EDX studies were normal in two cases, and demyelinating abnormalities appeared on follow-up